Thiogenesis Therapeutics, Corp.
TTIPF
$0.58
$0.00-0.27%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.89M | -3.64M | -2.75M | -2.29M | -3.01M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 579.70K | 390.70K | 283.20K | 253.30K | 204.60K |
| Change in Net Operating Assets | 960.00K | 829.80K | 484.70K | -843.60K | -204.80K |
| Cash from Operations | -3.35M | -2.42M | -1.98M | -2.88M | -3.01M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.07M | 260.90K | 260.90K | 723.40K | 4.59M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.95M | 186.50K | 186.50K | 529.50K | 3.38M |
| Foreign Exchange rate Adjustments | -32.90K | -8.50K | -11.10K | -22.80K | 2.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -436.50K | -2.24M | -1.80M | -2.37M | 372.20K |